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BACKGROUND	 Genetic	 testing	 of	 familial	 Alzheimer’s	 disease	 (AD)	 and	 frontotemporal	 lobar	degeneration	(FTLD)	is	attracting	interest	thanks	to	innovative	primary	prevention	clinical	trials	and	increased	 request	 for	 information	 by	 at-risk	 individuals.	 However,	 ethical,	 social	 and	 psychological	implications	are	paramount	and	genetic	testing	must	be	supported	by	structured	genetic	counselling.	In	Italy,	practice	parameters	and	guidelines	for	genetic	counselling	in	dementia	are	not	available.	
AIM	To	develop	a	nationally	harmonized	protocol	for	genetic	counselling	and	testing	of	familial	AD	and	FTLD.	
METHODS	Activities	were	carried	out	 in	the	context	of	 the	Italian	Dominantly	Inherited	Alzheimer’s	and	 Frontotemporal	 Network	 (IT-DIAfN)	 project,	 a	 national	 network	 of	 centres	 of	 excellence	 with	expertise	 in	 managing	 patients	 with	 familial	 AD	 and	 FTLD.	 A	 survey	 of	 the	 literature	 on	 genetic	counselling	 protocols	 and	 guidelines	 was	 conducted.	 Local	 protocols	 for	 genetic	 counselling	 were	surveyed.	Differences	and	commonalities	among	protocols	were	identified	and	discussed	among	project	partners.	Consensus	was	reached	following	implicit	aggregation	methods.	
RESULTS	Consensus	was	reached	on	a	protocol	 for	patients	with	clinically	diagnosed	 familial	AD	or	FTLD	and	a	distinct	protocol	 for	 their	 at-risk	 relatives.	Genetic	 counselling	 should	be	provided	by	 a	multidisciplinary	 team	 including	 a	 geneticist,	 a	 neurologist/geriatrician,	 and	 a	psychologist/psychiatrist,	 according	 to	 the	 following	 schedule:	 (i)	 initial	 consultation	 with	 tailored	information	on	 the	genetics	of	 the	dementias;	 (ii)	 clinical,	psychological	and	cognitive	assessment;	 if	deemed	appropriate	(iii)	genetic	testing	following	a	structured	decision	tree	for	gene	mutation	search;	(iv)	genetic	testing	result	disclosure;	(v)	psychological	support	follow-up.	
CONCLUSIONS	This	genetic	counselling	protocol	provides	Italian	centres	with	a	line	of	shared	practice	for	 dealing	with	 the	 requests	 for	 genetic	 testing	 for	 familial	AD	 and	FTLD	 from	patients	 and	 at-risk	relatives,	who	may	also	be	eligible	participants	for	novel	prevention	clinical	trials.	 	
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1.	INTRODUCTION	Alzheimer’s	Disease	(AD)	and	frontotemporal	lobar	degeneration	(FTLD)	are	two	of	the	most	common	forms	of	dementia.	Although	the	majority	of	cases	are	sporadic	(i.e.	without	a	family	history),	a	markedly	familial	component	has	been	reported	in	60%	of	early	onset	(<65	years)	AD	patients	[1]	and	in	25-50%	of	FTLD	patients	[2,3].	An	autosomal	dominant	mode	of	inheritance	is	found	in	about	1-5%	of	AD	and	10-50%	 of	 FTLD	 cases	 [4,5]:	 specifically,	 pathogenic	 AD	 mutations	 were	 identified	 in	 the	 Amyloid	precursor	protein	(APP)	[6]	and	the	Presenilin	(PSEN1	and	PSEN2)	genes	[7,8],	while	the	genes	mainly	involved	 in	 FTLD	 are	 the	Microtubule	 associated	 protein	 tau	 (MAPT)	 [9-11],	 the	 Progranulin	 (GRN)	[12,13]	 and	 Chromosome	 9	 open	 reading	 frame	 72	 (C9orf72)	 [14,15].	 Since	 the	 majority	 of	 GRN	pathogenetic	mutations	cause	protein	haploinsufficiency,	the	dosage	of	circulating	progranulin	has	been	proposed	as	a	useful	tool	for	a	quick	and	inexpensive	large-scale	screening	of	GRN	mutations	carriers	[16-19].	Genetic	testing	for	AD	and	FTLD	is	changing	rapidly	due	to	the	increasing	availability	of	new	and	faster	technologies	for	DNA	test,	and	it	is	attracting	interest	from	patients	and	families	thanks	to	innovative	primary	prevention	clinical	trials	targeting	genetic	dementia	and	to	the	growing	request	for	information	by	 at-risk	 individuals.	 Two	 recent	 innovative	 clinical	 trials	 targeting	 genetic	 dementia	 are	 the	Dominantly	 Inherited	 Alzheimer	 Network	 Trial	 for	 AD	 (DIAN-TU,	www.clinicaltrials.gov/show/NCT01760005)	 and	 the	 Presymptomatic	 Neurodegeneration	 Initiative	for	 FTLD	 (PreNI,	 www.neurodegenerationresearch.eu/initiatives/jpnd-alignment-actions/longitudinal-cohorts/call-for-working-groups/call-results/).	 Genetic	 mutation	 carriers,	 both	symptomatic	and	asymptomatic,	could	therefore	be	eligible	participants	for	these	novel	clinical	trials.	Genetic	testing	in	symptomatic	patients	is	used	to	confirm	the	clinical	diagnosis	(diagnostic	DNA	test);	genetic	testing	in	cognitively	unimpaired	relatives	of	patients	with	a	mutation	identifies	those	who	will	develop	 the	 disease	 in	 the	 future	 (predictive	 DNA	 test)	 [20-23].	 In	 at-risk	 asymptomatic	 relatives,	predictive	genetic	testing	offers	the	possibility	of	assessing	their	personal	risk,	thus	allowing	them	to	organize	their	lives	and	make	informed	career	or	reproductive	choices	and	decision	[23].	Undergoing	predictive	 tests	may	help	at-risk	 individuals	 to	 cope	emotionally	with	 their	genetic	 risk	by	 reducing	uncertainty	about	their	status	and	focusing	on	planning	for	the	future	[24],	as	suggested	by	a	seminal	
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study	in	Huntington's	disease	[25].	As	compared	to	Americans,	Italian	at-risk	relatives	expressed	higher	intentions	to	undergo	genetic	testing	[20].	However,	 together	with	these	potential	advantages,	genetic	 tests	have	 important	ethical,	social,	 legal	and	 psychological	 implications	 for	 the	 patients	 and	 the	whole	 family.	 In	 fact,	 the	 identification	 of	 a	genetic	mutation	 in	a	patient	 implicitly	defines	 the	 risk	 for	 the	other	 family	members,	with	possible	implication	for	their	health	and	their	future.	On	the	other	hand,	information	on	genetic	status	cannot	be	sensibly	used	for	therapeutic	purposes,	as	no	approved	disease-modifying	treatment	is	available	to	date.	In	healthy	at-risk	individuals,	there	are	concerns	that	a	positive	genetic	testing	may	trigger	a	negative	psychological	response,	such	as	severe	depression,	anxiety,	helplessness,	or	even	suicidal	ideation	[26].	From	a	social/legal	perspective,	there	may	be	issues	of	potential	genetic	discrimination,	difficulties	in	finding	a	job	or	service	assistance	(including	insurance	implications),	and	in	creating	relationships	[21].	Current	 guidelines	 for	 AD	 and	 other	 inherited	 dementia	 recommend	 that	 genetic	 testing	 should	 be	offered	within	a	proper	genetic	counselling	procedure	[21].	For	asymptomatic	at-risk	individuals,	the	protocol	established	for	Huntington’s	disease	and	recently	revised	[27]	is	recommended.	With	the	advent	of	the	prevention	clinical	trials	in	dementia,	such	as	DIAN-TU	for	AD	in	pre-symptomatic	mutation	carriers,	disclosure	of	genetic	status	is	a	pre-condition	to	participate	in	a	trial	in	Italy.	Such	disclosure	cannot	be	made	without	effective	pre-	and	post-genetic	testing	support	[28].	To	 date,	 in	 Italy	 no	 practice	 standards	 and	 consensus-based	 guidelines	 are	 available	 for	 genetic	counselling	of	familial	AD	or	FTLD.	The	IT-DIAfN	project,	a	network	of	Italian	centres	of	excellence	with	recognized	 experience	 in	 managing	 patients	 with	 familial	 AD	 and	 FTLD,	 aimed	 at	 developing	 a	harmonized	 and	 structured	 protocol	 for	 genetic	 testing	 and	 counselling	 for	 those	 families,	 both	 for	symptomatic	patients	and	at-risk	relatives.	As	inherited	AD	and	FTLD	are	genetically	heterogeneous	and	symptoms	often	overlap,	we	also	generated	a	decision	tree	to	assist	clinicians/researchers	in	mutations	search.		 	
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2.	METHODS	This	study	was	conducted	as	part	of	the	"Italian	Dominantly	Inherited	Alzheimer’s	and	Frontotemporal	Network	(IT-DIAfN)",	a	national	project	 funded	by	 the	 Italian	Ministry	of	Health	 (RF-2010-2319722,	Bando	Ricerca	Finalizzata	2010).	It	gathers	six	centres	of	excellence	in	the	study	of	genetic	AD	and	FTLD:	IRCCS	 Istituto	 Centro	 San	 Giovanni	 di	 Dio	 Fatebenefratelli	 of	 Brescia,	 IRCCS	 Fondazione	 Istituto	Neurologico	Carlo	Besta	of	Milan,	University	of	Florence,	Centro	Regionale	di	Neurogenetica	of	Lamezia	Terme,	University	of	Brescia,	and	Fondazione	IRCCS	Cà	Granda	Ospedale	Maggiore	Policlinico	of	Milan.	A	working	group	was	composed	by	geneticists,	psychologists,	neurologists,	and	bioethicists,	with	at	least	one	 representative	 from	 each	 centre,	 with	 the	 collaboration	 of	 the	 Department	 of	 Health	 Sciences,	University	of	Genova	and	Division	of	Medical	Genetics,	Galliera	Hospital,	Genova.	As	a	first	step,	the	group	conducted	a	survey	of	genetic	counselling	protocols	approved	by	the	local	ethics	committees	 and	 in	 use	 at	 each	 centre.	 In	 particular,	 the	 group	 collected	 information	 regarding	 the	professionals	 involved	 in	 the	 genetic	 counselling	 team,	 tests	 used	 for	 the	 assessment,	 phases,	procedures,	timelines,	informed	consent	forms,	access	criteria	and	specific	requests	from	the	local	ethics	committees.	Moreover,	other	specific	issues	were	addressed,	such	as	the	informed	consent/refusal	for	storage	of	the	biological	samples	in	a	biobank	for	possible	future	research	studies.	Literature	search	and	experience	from	centres	were	combined	to	develop	a	decision	tree	to	assist	in	the	search	of	the	mutation,	to	be	more	accurate,	and	to	reduce	time	and	cost.	A	literature	search	was	conducted	to	analyse	guidelines	or	recommendations	available	for	other	genetic	diseases,	such	as	Huntington's	disease	[27,29,30],	or	 in	use	 in	other	countries.	 Italian	regulations	for	data	 protection	 were	 considered	 (The	 Italian	 Data	 Protection	 Authority,	 General	 Authorisation	 No.	8/2014	for	the	Processing	of	Genetic	Data,	doc.	web	No.	3632835).	In	February-March	2013	the	working	group	participated	in	the	first	meetings	(one	in-person	and	one	a	
remoto,	 via	 teleconferences)	 aimed	 at	 identifying	 and	 discussing	 the	 surveyed	 differences	 and	commonalities	among	protocols.	The	first	draft	was	discussed	during	an	in-person	meeting	in	July	2013	and	 circulated	 to	 the	 working	 group	 in	 the	 ensuing	 months.	 All	 comments	 and	 feedbacks	 were	periodically	summarized	and	collated	by	the	Project	Coordinator,	who	was	in	charge	of	moderating	the	discussion	 via	 electronic	 communication	 and	 of	 reconciling	 the	 different	 viewpoints	 to	 reach	 a	
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consensus.	The	final	consensus	was	reached	in	October	2014	following	implicit	aggregation	methods	[31]:	the	group	experts	in	each	field	guided	the	decision-making	process	and	the	final	consensus	was	defined	 by	 majority	 position.	 Further	 comments	 from	 SINdem	 (Italian	 Society	 for	 the	 study	 of	Dementias)	were	also	taken	into	account.	The	 harmonized	 protocol	 for	 genetic	 counselling	 was	 approved	 in	 February	 2015	 by	 the	 Ethics	Committee	of	the	Coordinating	Centre	of	the	IT-DIAfN	project	(IRCCS	Istituto	Centro	San	Giovanni	di	Dio	Fatebenefratelli	of	Brescia).		
3.	RESULTS	
3.1	Survey	for	local	protocols	The	results	of	the	survey	are	reported	in	Table	1.	In	all	centres	genetic	counselling	was	provided	by	a	multidisciplinary	 team,	 including	 a	 geneticist,	 a	 neurologist,	 a	 psychologist	 or	 a	 psychiatrist.	 The	schedule	 of	 the	 consultation	 and	 the	 procedures	 varied	 among	 centres.	 Three	 centres	 divided	 the	procedure	into	three	consultations:	the	first	was	an	informational	meeting,	where	the	family	history	was	collected	and	the	subjects	underwent	a	neurological	and	a	psychological	examination;	the	second	was	the	blood	sample	collection,	while	the	third	was	the	disclosure	of	the	genetic	test	results.	The	other	three	centres	divided	the	pre-test	phase	into	two	visits:	one	informational	and	one	for	the	assessment	of	the	patient.	 The	 timetable	 for	 the	 visits	 and	 for	 the	 supportive	 follow-up	 varied	 from	 centre	 to	 centre.	Moreover,	some	centres	considered	the	follow-up	as	non	mandatory	or	they	offered	it	only	in	case	of	positivity	at	the	test.	Different	tests	were	used	to	assess	different	domains	locally	(Table	1).	Only	two	centres	 had	 a	 specific	 protocol	 for	 symptomatic	 subjects	 (diagnostic	 test),	 while	 all	 centres	 had	 a	protocol	for	at-risk	relatives.		
3.2	Harmonized	protocol	for	genetic	counselling	
3.2.1	Target	population	Genetic	 counselling	 can	 be	 requested	 (and	 eventually	 stopped	 or	 suspended	 at	 any	 stage)	 by	 (i)	symptomatic	patients	with	a	positive	family	history	suggestive	of	an	autosomal	dominant	genetic	cause	for	AD	and	FTLD	and	(ii)	relatives	of	patients	with	proven	genetic	AD	or	FTLD.	Each	subject	has	to	be	≥	
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18	years	old.	A	positive	family	history	is	defined	within	the	group	based	on	the	presence	of	one	of	the	following	criteria:	i)	at	least	three	affected	first-degree	relatives	in	two	generations,	irrespectively	of	the	age	at	onset;	 ii)	at	 least	 two	affected	first-degree	relatives	 in	two	generations,	with	at	 least	one	with	onset	at	≤	65	years;	or	iii)	one	affected	family	member	with	onset	at	≤	60	years	or	with	a	suggestive	clinical	phenotype	(e.g.	dementia	with	atypical	presentation	[32],	recurring	presence	in	other	relatives,	peculiar	geographic	origin).	Cognitively	unimpaired	at-risk	relatives	enter	the	counselling	and	are	eligible	to	undergo	the	genetic	testing	only	after	the	proven	presence	of	the	mutation	in	a	first-degree	symptomatic	relative.	Two	specific	genetic	counselling	protocols	were	defined:	one	for	symptomatic	patients	(Section	3.2.4)	and	one	for	at-risk	relatives,	with	a	more	relaxed	and	prolonged	schedule	(Section	3.2.5).		
3.2.2	Genetic	Counselling	Team	Genetic	counselling	is	provided	by	a	multidisciplinary	team	of	health	professionals	who	work	together	to	provide	an	individual	or	a	family	with	current	information	and	supportive	counselling	about	genetic	testing.	Genetic	counselling	is	structured	and	guided	by	a	Geneticist	and	by	a	Specialized	Medical	Doctor	with	 specific	 competences	 in	 neurodegenerative	 diseases.	 The	 Geneticist	 is	 a	 specialist	 in	 medical	genetics	with	expertise	in	neurodegenerative	diseases,	who	had	education	in	genetic	counselling.	The	Specialized	Medical	Doctor	(Neurologist,	Geriatrician,	and/or	Psychiatrist)	is	the	clinical	contact	person	for	the	patient:	this	role	can	be	also	played	by	the	geneticist,	but	only	if	he/she	is	a	medical	doctor	with	a	 consolidated	 clinical	 background	 for	 the	 aforementioned	 diseases.	 Beside	 the	 Geneticist	 and	 the	Specialized	 Medical	 Doctor,	 the	 multidisciplinary	 team	 is	 composed	 by	 other	 professionals	 (i.e.	 a	Psychologist	and/or	a	Psychiatrist),	who	have	expertise	in	counselling,	and	have	skills	at	providing	on-going	support	to	individuals	with	possible	socio-psychological	consequences	associated	with	the	risk	of	being	a	mutation	carrier.		
3.2.3	Evaluation	Tests	A	common	battery	of	clinical,	psychological	and	cognitive	tests	was	defined	for	symptomatic	patients	and	their	at-risk	relatives.	Specifically,	the	battery	includes	the	Mini-Mental	State	Examination	(MMSE)	
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[33]	and	the	Clinical	Dementia	Rating	Scale	(CDR)	[34],	the	Questionnaire	on	the	Health	Status	-	12	(SF-12)	[35]	and	the	World	Health	Organization	Quality	of	Life	(WHOQOL)	[36],	for	the	assessment	of	quality	of	life	and	health	status;	the	State	Trait	Anxiety	Inventory	(STAI-Y)	[37],	the	Beck	Depression	Inventory	(BDI)	 [38]	 and	 the	 Hamilton	 Rating	 Scale	 for	 Depression	 (HRSD)	 [39],	 for	 anxiety	 and	 depression	measurement;	the	Brief	COPE	(BC)	[40],	the	Resilience	Scale	for	Adult	(RSA)	[41]	and	the	Health	Locus	of	Control	(HLC)	[42,43],	for	the	evaluation	of	the	coping	style	and	the	locus	of	controls.	Moreover,	a	depth	 evaluation	 of	 the	 risk	 of	 suicide	 is	 recommended,	 if	 the	 subject	 showed	 suicidal	 thoughts	 or	attitudes	in	the	past	or	at	present	(item	9	of	BDI	and/or	item	3	of	HRSD).	One	suggested	scale	is	the	Beck	Hopelessness	Scale	[44,45].	In	addition	to	these	tests,	the	at-risk	relatives	are	also	assessed	with	the	Big	Five	Questionnaire	(BFQ)	for	personality	assessment	[46,47].	The	subject	 is	assessed	at	a	pre-test	phase,	 to	 investigate	his/her	ability	to	cope	with	the	test	result.	Except	for	the	MMSE,	the	CDR	and	the	BFQ,	the	assessment	with	the	other	tests	is	repeated	post-test	at	different	time-points,	to	monitor	the	psychological	status	of	the	subject,	as	specified	later	in	the	text	and	in	Figure	1A-B.	Based	on	the	profile	of	the	subject,	the	multidisciplinary	team	can	suggest	to	postpone	the	genetic	test.	The	team	continues	to	follow	and	support	the	individual	as	long	as	it	is	deemed	necessary	by	the	team	or	requested	by	the	subject.		
3.2.4	Protocol	for	Symptomatic	Subjects	The	genetic	testing	for	symptomatic	subjects	has	a	diagnostic	purpose,	i.e.	to	identify	the	genetic	cause	of	the	disease	and	confirm	the	diagnosis	of	AD	or	FTLD.	The	procedures	are	illustrated	in	Figure	1A	and	include:	at	least	one	pre-test	consultation,	one	meeting	for	blood	withdrawal	for	the	genetic	testing,	a	post-test	consultation,	where	the	genetic	status	is	disclosed	(for	those	who	wish	to	know)	and	then	three	follow-ups.	The	number	of	the	consultations	can	be	increased	and	the	timespan	relaxed,	if	required	by	the	 patients	 of	 if	 considered	 appropriate	 by	 the	 team.	Genetic	 counselling	 for	 symptomatic	 patients	should	be	performed	in	the	presence	of	the	caregiver	according	to	patient's	will,	and	the	individual’s	legal	guardian	if	appointed	for	the	individual	patient,	to	help	the	patient	in	the	decision-making	process,	
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specifically	to	help	in	understanding	and	appreciating	the	purpose	and	possible	results	of	the	genetic	test	and	in	expressing	a	choice	[21,	48].		
3.2.4.1	First	consultation:	Pre-test	During	 the	 first	 informational	 visit,	 the	 whole	 multidisciplinary	 team	 provides	 general	 information	regarding	the	familial	forms	of	dementia	and	details	about	genetic	counselling	(i.e.	timespan,	team	roles,	aims	and	procedures),	the	reliability	of	the	test	and	the	interpretation	of	the	results.	The	team	should	explain	medical	 and	genetic	 terms	and	avoid	 technical	 jargon.	The	 implications	of	both	positive	and	negative	test	result	are	discussed,	as	well	as	 if	and	how	these	results	will	be	communicated	to	other	family	members.	Patients	and	their	families	should	understand	that	multiple	possible	results	may	be	revealed:	a	causative	mutation	in	one	of	the	genes,	no	mutation	in	any	of	the	genes,	a	variant	of	unknown	significance,	or	even	mutations	or	variants	 in	more	 than	one	genes.	 Supportive	 information	 is	 given	regarding	 the	 diagnosis	 and	 risk	 for	 the	 genetic	 disease	 in	 the	 family	 and	 its	 clinical,	 psychological,	sociological	 and	 ethical	 implications,	 together	with	 the	 impact	 on	 the	 family	members.	 The	 specific	implications,	prospective	benefits	and	risks	of	undergoing	genetic	testing	are	discussed.	The	aim	is	to	provide	as	much	clear	information	as	possible,	and	discuss	any	question	or	doubt,	to	allow	subjects	to	take	an	autonomous	and	informed	decision	whether	they	are	willing	to	undergo	genetic	counselling	and	testing	and	to	know	their	genetic	status.	The	team	avoids	to	influence	the	decision	of	the	individual	and	the	family,	and	aims	at	facilitating	their	autonomous	decision	making.	If	 agreed,	 the	 subject,	 and/or	 his/her	 legal	 guardian	 on	 his/her	 behalf	 if	 appropriated,	 signs	 the	informed	consent	form	for	genetic	counselling.	The	caregiver,	if	present	according	to	patient's	wishes,	can	also	sign	the	informed	consent	to	express	agreement	[48].	The	family	health	history	is	collected	to	construct	the	family	pedigree	and,	where	possible,	a	complete	family	history	should	be	collected	using	a	 structured	questionnaire.	Personal	 clinical	phenotype	and	 family	history	will	 be	used	 to	guide	 the	algorithm	 for	mutation	 search	 (see	3.2.6	Flowchart	 for	 genetic	 testing)	 and	 to	 evaluate	whether	 the	genetic	test	is	appropriate	(as	a	guide:	[49,50]).	Finally,	if	not	too	severely	impaired,	the	subject	is	assessed	using	the	test	described	in	3.2.3	Evaluation	Tests.	
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After	the	consultation,	the	team	provides	the	patient	with	a	written	summary	or	brochure	with	all	the	general	 information	 discussed	 in	 person,	 to	 allow	 their	 elaboration	 and	 comprehension.	 In	 case	 of	doubts,	a	second	informational	visit	can	be	scheduled.		
3.2.4.2	Second	consultation:	Blood	Sample	Collection	At	 the	 beginning	 of	 the	 second	 consultation,	 the	whole	 team	 evaluates	whether	 all	 the	 information	provided	 during	 the	 first	 visit	 was	 fully	 understood,	 and	 it	 clarifies	 any	 remaining	 doubts	 or	 new	questions	that	may	arise.	The	results	of	the	assessment	(if	done)	are	discussed.	If	the	patient	wishes	to	proceed	with	the	test,	the	subject,	and/or	his/her	legal	guardian	on	his/her	behalf	if	appropriated,	signs	the	 informed	 consent	 for	 genetic	 testing	 and	 blood	 sample	 is	 collected.	 The	 caregiver,	 if	 present	according	to	patient's	wishes,	can	also	sign	the	informed	consent	to	express	agreement.	At	this	stage,	the	patient	can	decide	whether	his/her	sample	can	be	stored	in	a	biobank	for	possible	future	research	studies	on	genetic	forms	of	dementia	or	destroyed	after	the	completion	of	the	analyses.	The	 team	 informs	 the	 patient	 about	 the	 timespan	 for	 the	 completion	 of	 molecular	 genetic	 analysis	(around	two	months).		
3.2.4.3	Third	consultation:	Post-test	Within	two	months	from	the	blood	sample	collection,	the	results	are	made	available.	If	the	patient	still	wishes	 to	know,	 the	 genetic	 test	 results	 are	disclosed	and	discussed	with	 the	patient,	 and	a	written	report	is	given.	The	whole	team	should	assess	the	individual’s	understanding	of	his/her	situation	and	adapt	 the	 language	 to	 the	 patient	 in	 order	 to	 clearly	 explain	 the	meaning	 and	 the	 implications	 of	 a	positive,	negative,	or	unclear	test	result.	The	team	should	support	and	assist	the	patient	and	the	family	in	expressing	their	emotional	reactions	to	 their	 genetic	 status.	 Before	 leaving	 the	 visit,	 the	 presence	 of	 psychological	 distress	 should	 be	informally	assessed.		
3.2.4.4	Follow-up	
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After	the	disclosure	of	the	results,	the	team	offers	on-going	support	and	information.	Three	different	time	points	 for	 the	 follow-up	were	defined:	 after	1,	6	and	12	months	 from	 the	disclosure.	The	 team	collects	information	about	any	possible	change	occurred	in	the	family	and	in	his/her	everyday	life.	The	patient	is	qualitatively	assessed	about	his/her	psychological	conditions,	and	the	tests	described	in	3.2.3	Evaluation	Tests	are	administered,	whenever	possible.		
3.2.5	Protocol	for	At-risk	Subjects	The	predictive	test	in	genetic	counselling	aims	at	confirming	whether	the	genetic	mutation	identified	in	the	family	has	been	inherited	by	the	at-risk	relative,	at	a	stage	where	the	individual	does	not	present	any	symptom.	This	protocol	arises	much	more	ethical	and	psychosocial	issues	that	the	diagnostic	test	in	symptomatic	subjects,	because	the	potential	identification	as	being	carrier	of	an	autosomal	dominant	mutation	 almost	 certainly	 predicts	 the	 future	 development	 of	 the	 disease	 in	 an	 individual	 currently	healthy.	Undergoing	a	predictive	test	is	a	highly	personal	decision	that	demands	extensive	counselling.	The	procedures	are	illustrated	in	Figure	1B	and	detailed	below.	The	schedule	mainly	differs	from	the	diagnostic	test	in	prescribing	at	least	two	pre-test	consultations	before	the	genetic	testing,	and	in	having	a	phone	call	one	week	after	the	disclosure	of	the	genetic	status.		
3.2.5.1	First	consultation:	Pre-test	As	for	the	symptomatic	patients,	the	first	consultation	is	an	informational	and	supporting	visit,	when	the	whole	team	covers	specific	issues	of	the	familial	forms	of	dementia,	genetic	counselling	and	testing,	and	 the	 implications	 of	 the	 results	 (for	 further	 details	 see	 3.2.4.1	 First	 consultation:	 Pre-test).	 The	presence	of	a	support	person	is	encouraged.	If	 agreed,	 the	 subject	 signs	 the	 informed	 consent	 form	 for	 genetic	 counselling.	 Then,	 there	 is	 an	evaluation	of	the	personal	and	familial	medical	history.	After	the	consultation,	the	team	provides	the	subject	with	a	written	summary	or	brochure	with	all	the	general	information	discussed	in	person,	to	allow	their	elaboration	and	comprehension.		
3.2.5.2	Second	consultation:	Pre-test	
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After	one	month	from	the	first	visit,	the	second	one	is	scheduled,	to	further	discuss	the	motivation	for	the	predictive	test	and	clarify	any	doubts	which	may	have	arisen.	The	subject	is	assessed	using	the	tests	described	in	3.2.3	Evaluation	Tests.		
3.2.5.3	Third	consultation:	Blood	Sample	Collection	The	procedures	are	the	same	as	for	the	symptomatic	protocol	(see	3.2.4.2	Second	consultation:	Blood	Sample	Collection).		
3.2.5.4	Fourth	consultation:	Post-test	The	procedures	are	the	same	as	for	the	symptomatic	protocol	(see	3.2.4.3	Third	consultation:	Post-test).		
3.2.5.5	Follow-up	One	week	after	the	disclosure	of	the	results,	the	team	(specifically	the	Psychologist	and/or	Psychiatrist),	contacts	the	subject	by	phone	and	offers	on-going	support	and	information.	The	other	follow-up	visits	are	the	same	as	for	the	symptomatic	protocol	(see	3.2.4.4	Follow-up).		
3.2.6	Flowchart	for	genetic	testing	A	decision	tree	was	developed	to	assist	in	the	search	of	the	mutation	in	symptomatic	patients	(Figure	2).	If	the	patient	has	recently	undergone	a	lumbar	puncture	and	Aβ	and	tau	levels	in	the	cerebrospinal	fluid	(CSF)	have	been	analyzed,	this	measure	guides	the	genetic	screening.	If	the	CSF	tau	and	Aβ42levels	are	abnormal	(i.e.	tau/Aβ42>0.52)	[51],	genetic	mutations	linked	to	AD	are	searched	as	first.	To	determine	which	 gene	 should	 be	 sequenced	 first	 (i.e.,	 APP,	 PSEN1,	 or	 PSEN2),	 patient’s	 age	 at	 onset	 (AAO)	 is	considered:	if	the	patient	has	an	early	age	at	onset	(≤65	years),	APP	gene	(exons	16-17)	is	sequenced;	if	negative:	 all	 PSEN1	 exons	 and	 flanking	 regions;	 if	 negative:	 all	 PSEN2	 exons	 and	 flanking	 regions.	Instead,	if	the	patient	has	a	late	age	at	onset,	PSEN2	gene	is	the	first	choice	for	sequencing,	and	then	APP	and	 PSEN1.	 If	 all	 AD	 genes	 are	mutation-negative,	 but	 there	 is	 a	 strong	 evidence	 for	 an	 autosomal	dominant	pattern,	 then	genes	 linked	 to	FTLD	are	 screened.	Plasma	progranulin	dosage	 for	GRN	 null	
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mutation	screening	has	the	priority:	if	the	level	is	<61.55	ng/ml	[19],	the	presence	of	the	common	Italian	p.L271fs	(exon8:c.811_814del,	ref	sequence	NM_002087)	mutation	is	assessed	[52];	if	no	mutation	is	found,	 all	 other	 exons	 are	 sequenced.	 Conversely,	 if	 the	 progranulin	 level	 is	 not	 suggestive	 for	 the	presence	of	null	mutations	 (i.e.	>61.55	ng/ml),	 the	 clinical	phenotype	 is	 taken	 into	account.	C9orf72	genetic	 screening	 should	 have	 the	 priority	 in	 patients	with	 FTLD	 and	Motor	Neuron	Disease	 (FTD–MND),	behavioural	variant	frontotemporal	dementia	(bvFTD)	with	psychosis,	or	FTLD	with	cerebellar	features,	while	MAPT	gene	(exons	1,	9-13,	as	first)	should	be	the	first	choice	in	patients	with	bvFTD	and	semantic	dementia,	progressive	sopranuclear	palsy	(PSP),	corticobasal	syndrome	(CBS)	or	an	early	age	at	onset	(AAO<60	years).	When	both	C9orf72	and	MAPT	resulted	negative,	then	GRN	should	be	tested,	given	possible	false	negative	in	progranulin	plasma	screening.	When	CSF	 tau	 and	Aβ	 levels	 are	normal	 or	not	 available,	 the	 algorithm	 is	 based	on	 the	progranulin	dosage,	as	described	previously.	When	patient's	level	of	progranulin	is	normal,	the	clinical	phenotype	is	taken	 into	 account	 for	 guiding	 the	 analysis.	 If	 the	 clinical	 phenotype	 is	 FTD-like,	 then	 the	 priority	between	C9orf72	and	MAPT	 is	defined	as	previously	described.	If	the	clinical	phenotype	is	consistent	with	 AD,	 then,	 according	 to	 the	 age	 at	 onset,	 APP,	 PSEN1	 and	 PSEN2	 are	 screened	 as	 described	previously.	When	no	mutation	is	found,	the	other	branch	in	the	diagram	is	followed	(Figure	2).	Lastly,	 if	 the	DNA	analysis	 is	done	 in	an	at-risk	subject,	only	 the	mutation	 found	 in	 the	symptomatic	relative	is	searched	for.	
	
4.	DISCUSSION	Genetic	 testing	has	 ethical,	 social,	 legal	 and	psychological	 implications	 for	 patients	 and	 their	 family:	when	 handled	 by	 an	 experienced	 and	 qualified	multidisciplinary	 team	 following	 structured	 criteria,	these	 issues	 can	 be	 faced	 serenely	 and	 confidently	 by	 families.	 Here,	 we	 present	 a	 standard	 and	structured	 protocol	 for	 genetic	 testing	 and	 counselling	 for	 symptomatic	 and	 at-risk	 individuals	belonging	 to	 families	with	suspected	 forms	of	autosomal	dominant	AD	or	FTLD.	This	protocol	 is	not	designed	 for	 genetic	 counseling	 of	 people	 who	 carry	 susceptibility	 genetic	 risk	 for	 AD,	 such	 as	 the	Apolipoprotein	E	e4	allele,	as	this	is	only	a	risk	factor	for	dementia	and	no	definitive	prediction	can	be	made	 about	 dementia	 in	 these	 subjects.	 Moreover,	 based	 on	 the	 current	 knowledge,	 we	would	 not	
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recommend	genetic	counselling	to	all	sporadic	FTD	cases	as	the	likelihood	of	finding	a	mutation	in	cases	with	a	negative	family	history	is	presumably	low	[49]	and	would	thus	unnecessarily	increase	burden	to	patients	and	their	families.	The	IT-DIAfN	protocol	provides	guidance	on	the	schedule,	the	procedures,	the	tests	and	the	professional	figures	involved	in	genetic	counselling,	with	the	aim	to	support	and	take	responsible	 care	 of	 these	 families.	 The	 tests	 for	 clinical,	 cognitive	 and	 personality	 assessment	were	accurately	chosen	to	obtain	a	concise	but	accurate	profile	of	the	individual,	helping	in	personalizing	and	adapting	the	support	within	the	counselling	to	his/her	possible	reactions.	
We	have	taken	into	account	the	guidelines	for	the	genetic	testing	of	Huntington's	disease	[27,29,30],	which	is	considered	the	gold	standard	for	genetic	testing	for	adult	onset	diseases.	As	recommend	by	these	guidelines,	we	used	a	multidisciplinary	approach	to	facilitate	the	subject's	autonomous	decision	making:	 the	Geneticist	as	 the	expert	 in	genetic	counselling	 for	AD	and	FTLD,	 the	Specialized	Medical	Doctor	as	the	clinical	contact	person	of	the	patients;	and	the	Psychologist/Psychiatrist	as	the	contact	person	for	counselling,	psychological	appraisal	and	support.	The	schedule	and	timespan	of	the	visits	are	similar	to	those	defined	for	Huntington's	disease:	several	sessions	and	phases	(pre-,	post-testing	and	follow-ups)	are	crucial	to	allow	free	choice,	without	rushing	into	genetic	testing	before	all	the	necessary	explanations	and	information	are	given.	Other	recommendations	prescribed	in	the	Huntington's	disease	guidelines	were	adopted	here:	i)	disclosure	of	the	genetic	status	is	provided	both	orally	and	through	a	written	report;	 ii)	availability	of	 the	 test	only	 to	 individuals	who	have	come	of	age;	 iii)	possibility	of	storing	the	biological	samples	in	a	biobank	for	research	studies	after	signing	the	informed	consent.	
As	described	in	other	existent	counselling	protocols	for	AD	and	FTLD	[21,22],	we	recommended	that	i)	the	 legal	 guardian	 of	 the	 symptomatic	 patient	 is	 present	 during	 the	 counselling	 to	 help	 her/him	 in	understanding	its	purpose	and	possible	results	of	the	genetic	test	and	in	expressing	a	choice	,	and	that	ii)	a	symptomatic	family	member	should	be	tested	before	an	at-risk	individual.	
The	guidelines	for	genetic	counselling	for	AD	defined	by	the	American	College	of	Medical	Genetics	and	the	National	 Society	of	Genetic	Counsellors	 [21]	 specified	 that	genetic	 counselling	 could	be	done	 in-person	or	through	videoconferences.	The	Huntington's	disease	guidelines	clearly	stated	that	the	results	of	the	test	should	be	revealed	in-person,	and	not	by	phone	or	mail	[27,30],	while	psychosocial	support	
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should	be	available	close	to	the	person’s	community,	by	phone	or	telemedicine	where	necessary.	A	few	pilot	projects	demonstrated	that	telemedicine	can	be	used	to	offer	medical	genetics	service	on	a	remote	basis	 [53].	 Preliminary	 evidence	 suggests	 that	 genetic	 counselling	 can	 be	 effectively	 delivered	 in	underserved	 areas,	 also	 in	 late-onset	 genetic	 disorders	 such	 as	 familial	 cancer	 [54].	 The	 advent	 of	telegenetics	 could	 allow	 the	 implementation	 of	 this	 genetic	 counselling	 protocol	 in	 clinical	 research	centres	without	lowering	the	clinical	standard;	it	may	also	facilitate	the	enrolment	in	clinical	trials	of	individuals	who	could	not	access	to	tertiary	care	genetics	centres.	Nevertheless,	it	is	recommended	that	the	Psychologist/Psychiatrist	should	be	always	present	in	person	during	the	visits.	
We	 developed	 two	 specific	 paths,	 one	 for	 symptomatic	 patients	 and	 one	 for	 asymptomatic	 at-risk	subjects,	being	aware	of	the	difference	of	the	two	scenarios.	 In	fact,	 in	symptomatic	subjects,	genetic	testing	is	aimed	at	confirming	the	clinical	diagnosis	and	the	genetic	cause	of	the	disease.	A	positive	result	can	provoke	hopelessness	and	sense	of	guilty	for	the	possibility	of	transmission	of	the	mutation	to	the	offspring.	In	the	case	of	asymptomatic	subjects	psychological,	social	and	ethical	issues	are	even	more	critical,	especially	in	the	absence	of	prevention	or	treatment	options:	a	correct	and	careful	counselling	will	offer	them	the	option	of	knowing	their	condition,	cope	positively	with	their	future	and	eventually	they	might	be	offered	the	possibility	to	enter	a	novel	prevention	clinical	trial.	It	must	be	underlined	that	a	 negative	 result	 has	 different	meanings	 according	 to	 the	 two	different	 scenarios:	 in	 a	 symptomatic	subject,	this	could	not	exclude	definitely	that	the	disease	has	a	genetic	cause	(thus	it	is	sporadic),	because	an	 unknown/new	mutation	 could	 be	 present	 but	 not	 yet	 been	 discovered;	 in	 an	 at-risk	 relative,	 a	negative	 result	 confirms	 almost	with	 absolute	 certainty	 that	 he/she	 has	 not	 inherited	 the	 causative	mutation	found	in	the	affected	relative	and	thus	he/she	has	the	same	risk	of	the	general	population	to	develop	the	disease	in	the	future.	
Considering	 the	 results	 reported	 in	 Binetti	 et	 al.,	 2006	 [20],	 Italian	 families	 with	 familial	 dementia	showed	poor	knowledge	of	 the	disease	and	poor	awareness	of	personal	risk	of	developing	dementia	during	lifetime.	This	means	that	the	first	consultation	should	address	these	aspects	in	details,	guiding	families	to	a	free	and	informed	choice.	
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We	developed	a	step-by-step	algorithm	for	guiding	genetic	screening	on	the	basis	of	biomarker	results	and	clinical	data,	to	reduce	time	and	cost	of	the	laboratory	analysis.	Specifically,	the	decision	tree	was	defined	according	to	(i)	the	observed	frequency	of	genes	in	specific	clinical	phenotypes	in	the	literature	[49,55-58],	and	specifically	in	Italian	clinical	series	[52,59-65],	(ii)	the	direct	experience	of	the	Italian	centres,	and	(iii)	practical	considerations,	e.g.	the	high	speed	and	low	cost	of	a	given	screening	procedure	(i.e.	 plasma	 progranulin	 dosage).	 In	 the	 future,	 other	 biomarkers	 can	 be	 taken	 into	 account	 and	implemented	within	the	flowchart,	such	as	the	amyloid	PET.	
The	research	protocol	reported	herein	reflects	the	current	practice	of	Italian	centres	taking	part	to	the	IT-DIAfN	 initiative.	 Should	 important	 innovations	be	 introduced	 in	 the	 clinical	practice	as	well	 as	 in	laboratory	analyses,	the	protocol	will	be	amended.	Following	the	wide	availability	of	next	generation	sequencing	 (NGS)	panels	 for	 the	molecular	 genetics	 analysis,	 the	decision	 tree	 is	 subject	 to	 changes	accordingly.	NGS	is	not	currently	applied	in	all	centers	participating	into	the	IT-DIAfN	framework,	but	appears	as	the	upcoming	technology	for	the	mutation	analysis	in	heterogeneous	genetic	disorders	such	as	AD	and	FTLD.	To	date,	the	NGS	approach	provides	the	simultaneous	analysis	of	a	panel	of	17	genes	(PRNP,	 PSEN1,	 PSEN2,	 APP,	 GRN,	 MAPT,	 TREM2,	 CHMP2B,	 CSF1R,	 FUS,	 ITM2B,	 NOTCH3,	 SERPINI1,	
TARDBP,	 TYROBP,	 VCP,	 SQSTM1).	 Other	 experimental	 panels	 of	 additional	 genes	 and	 SNP	polymorphisms	 are	 currently	 under	 development	 within	 the	 IT-DIAfN	 group.	 The	 mutation	 search	should	be	completed	with	two	PCR	analyses	of	the	C9orf72	hexanucleotide	repeat	expansion	and	the	octapeptide	repeat	region	of	PRNP	[66].	
This	protocol,	developed	by	experts	in	the	field,	provides	Italian	centres	with	a	line	of	shared	practice	for	offering	genetic	counselling	to	eligible	individuals	who	may	benefit	from	genetic	testing	for	familial	AD	 and	 FTLD,	 and	 recruit	 them	 through	 a	 procedure	 which	 is	 compliant	 with	 International	recommendations	and	good	practices.	
Future	 steps	 will	 be	 the	 validation	 of	 the	 harmonized	 protocol	 of	 genetic	 counselling.	 This	 will	 be	performed	in	two	steps:	i)	after	approval	by	local	ethics	committees,	the	protocol	will	be	implemented	in	all	centres	participating	into	the	IT-DIAfN	project;	ii)	data	from	each	centre	will	be	collected	and	the	results	from	the	pilot	stage	will	be	critically	reviewed	by	the	working	group	who	developed	the	protocol.	
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The	genetic	counselling	protocol	will	also	be	disseminated	through	medical	societies	and	proposals	for	amendments	will	be	acknowledged.	
We	are	 aware	 that	 the	entire	procedure,	 including	 counselling,	 repeated	assessments	 and	 testing,	 is	highly	 demanding,	 especially	 in	 terms	 of	 human	 resources.	 The	 procedure	 is	 expected	 to	 be	accomplished	 within	 a	 research	 environment	 by	 a	 multidisciplinary	 team	 in	 centres	 with	 specific	expertise	–	as	such	it	was	not	designed	to	be	applied	in	routine	clinical	practice	in	its	current	version.	In	the	light	of	the	suggestion	raised	during	the	validation	phase,	an	optimized	protocol	could	be	eventually	transferred	 to	 clinics,	 provided	 that	 evidence	 of	 clinical	 utility	 has	 been	 produced	 and	 a	 health	technology	assessment	has	supported	its	implementation	in	clinical	practice.	
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Table	1.	Survey	of	the	genetic	counseling	protocols	in	use	at	the	local	centres.		
	 IRCCS	Istituto	Centro	San	Giovanni	di	Dio	
Fatebenefratelli	
Brescia	
IRCCS	
Fondazione	
Istituto	
Neurologico	
Carlo	Besta	
Milano	
Spedali	Civili/	
Università	di	Brescia	 Università	di	Firenze	 Centro	Regionale	Neurogenetica	Lamezia	Terme	
Fondazione	
IRCCS		
Cà	Granda	
Ospedale	
Maggiore	
Policlinico	
Milano	
Scheduling	
and	phases	
3	Consultations	(+	follow	up)	 3	Consultations	(+	follow	up)	 4	Consultations	(+	follow	up)	 4	Consultations	(+	follow	up)	 4	Consultations	(+	follow	up)	 3	Consultations	(+	follow	up)	
1-	Informational	meeting,	Family	health	history	collection,	psychosocial	assessment,	neurological	examination,	
1-	Informational	meeting,	Family	health	history	collection,	psychological	questionnaires,	neurological	examination	
1-	Informational	meeting,	Family	health	history	collection	 1-	Family	health	history	collection,	neuropsychological	assessment,	neurological	examination	and	informational	meeting	on	the	disease	
1-	Family	health	history	collection,	neuropsychological	and	personality	assessment,	neurological	examination	
1-	Informational	meeting,	Family	health	history	collection,	psychological	questionnaires,	neurological	examination	
	 	 2-	Psychological	assessment,	neuropsychological	assessment,	neurological	examination	
2-	Informational	meeting	on	the	genetic	risk	and	the	genetic	test	
2-	Informational	meeting	 	
2-	Blood	sample	collection	 2-	Blood	sample	collection	 3-	Blood	sample	collection	 3-	Blood	sample	collection	 3-	Blood	sample	collection	 2-	Blood	sample	collection	
3-	Disclosure	of	genetic	test	result	 3-	Disclosure	of	genetic	test	result	 4-	Disclosure	of	genetic	test	result	 4-	Disclosure	of	genetic	test	result	 4-	Disclosure	of	genetic	test	result	 3-	Disclosure	of	genetic	test	result	
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Professionals	
in	the	Team	 Neurologist,	Geneticist,	Psychiatrist,	Psychologist	
Neurologist,	Geneticist,	Psychiatrist,	Psychologist	 Neurologist,	Geneticist,	Psychiatrist,	Psychologist	
Neurologist,	Geneticist,	Psychiatrist,	Psychologist	
Neurologist,	Geneticist,	Psychiatrist,	Psychologist	
Neurologist,	Geneticist,	Psychiatrist,	Psychologist	
Timetable	 60	days	required	for	the	genetic	test	 Not	defined	 Not	defined	
About	1	month	between		first	and	second	consultation;	about	1	month	between	third	and	forth	consultation	
Blood	sample	is	taken	within	4	weeks	from	the	second	consultation	 Not	defined	
Follow	up	 At	12	and	24	months	(irrespective	of	test	result)	
At	6/12	months		(not	mandatory)	 At	15	and	30	days		(in	case	of	positivity	at	the	test)	 At	1,	3,	6	and	12	months	(irrespective	of	test	result)	 At	1,	3,	6	and	12	months	(irrespective	of	test	result)	
At	6/12	months		(not	mandatory)	
Clinical/	
Psychological,	
Cognitive	and	
Personality	
Test	
BDI,	STAI-Y,	BFQ,	GHQ,	ISS,	HLC,	SPQ,	SLEQ,	WHOQOL-100,	SDABE	
Psychological	self-administered	Questionnaires	
Semi-structured	interview,		MMPI-2,STAI,	ZUNG,	Neuropsychological	tests	 Neuropsychological	assessment	 MMPI,	Mental	Deterioration	Battery	 Psychological	self-administered	Questionnaires	
Protocols	 Diagnostic	and	Predictive	protocol	 Predictive	protocol	 Diagnostic	and	Predictive	protocol	 Predictive	protocol	 Predictive	protocol	 Predictive	protocol		Abbreviations:	BDI,	Beck	Depression	Inventory	[38];	STAI-Y,	State	Trait	Anxiety	Inventory	[37];	BFQ,	Big	Five	Questionnaire	[46,47];	GHQ,	General	Health	Questionnaire	[67];	ISS,	Information	Seeking	Style	[68];	HLC,	Health	Locus	of	Control	[42];	SPQ,	Social	Problem	Questionnaire	[69];	SLEQ,	Stressful	Life	Events	Questionnaire	[709];	WHOQOL-100,	The	World	Health	Organization	Quality	of	Life	assessment	[71];	SDABE,	Dementia	Attitudes	
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Beliefs	and	Experiences	[20,	72,73];	MMPI-2,	Minnesota	Multiphasic	Personality	Inventory-2	[74];	STAI,	State	Trait	Anxiety	Inventory	[75];	ZUNG,	Zung	self-rating	depression	and	anxiety	scales	[76,77];	Minnesota	Multiphasic	Personality	Inventory	[78];	Mental	Deterioration	Battery	[79].		
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Figure	1.	Genetic	Counselling	protocol.	Flowchart	for	symptomatic	subjects	(A)	and	for	at-risk	relatives	(B).		
A)	
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B)	
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Figure	2.	Genetic	Testing	Flowchart.	Step-by-step	algorithm	to	assist	in	the	search	of	genetic	mutations,	for	cases	with	abnormal	Aβ	and	tau	levels	in	the	cerebrospinal	fluid	(CSF)	(left	panel)	and	with	normal	CSF	values	or	data	not	available	(right	panel).	
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